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Epithelial cells orchestrate pulmonary homeostasis
and pathogen defense and play a crucial role in the
initiation of allergic immune responses. Maintaining
the balance between homeostasis and inappropriate
immune activation and associated pathology is
particularly complex at mucosal sites that are
exposed to billions of potentially antigenic particles
daily. We demonstrated that epithelial cell-derived
cytokine TGF-b had a central role in the generation
of the pulmonary immune response. Mice that spe-
cifically lacked epithelial cell-derived TGF-b1 dis-
played a reduction in type 2 innate lymphoid cells
(ILCs), resulting in suppression of interleukin-13
and hallmark features of the allergic response
including airway hyperreactivity. ILCs in the airway
lumen were primed to respond to TGF-b by express-
ing the receptor TGF-bRII and ILC chemoactivity was
enhanced by TGF-b. These data demonstrate that
resident epithelial cells instruct immune cells, high-
lighting the central role of the local environmental
niche in defining the nature and magnitude of im-
mune reactions.
INTRODUCTION
Regulation of innate immunity is essential for maintenance of im-
mune homeostasis, preventing inappropriate immune activation
and associated pathology. Maintaining this balance is particu-
larly complex at mucosal sites, which are exposed to billions of
potentially antigenic particles daily. For example, the pulmonary
immune system must be poised to respond quickly and effi-
ciently to inhaled pathogens such as respiratory viruses while
ignoring innocuous material from the inhaled environment such
as dust, pollen, and animal dander. Thus, an intricate network
of regulatory pathways is employed to facilitate maintenance
of homeostasis. Although regulatory T cells and interleukin-10
(IL-10) are an essential component of this system, the role of
transforming growth factor-b (TGF-b) is less clear. TGF-b pro-
motes the expression of the transcription factor FOXP3, therebyImfacilitating generation of CD4+CD25+ regulatory T (Treg) cells
that are able to inhibit allergic airway disease (Chen et al.,
2003; Kearley et al., 2005). Conversely, TGF-b also drives lineage
specificity in effector T cell subsets. Induction of the transcription
factor RORgT-dependent differentiation pathway in CD4+ T cells
can result in either T helper 17 (Th17) or Treg cells depending on
concomitant expression of maturation factors such as IL-6,
IL-21, retinoic acid, IL-23, and IL-10 (Travis and Sheppard,
2014). Similarly, a combination of TGF-b, IL-25, and IL-4 drives
Th9 cell generation (Dardalhon et al., 2008; Jones et al., 2012).
The collective activity of TGF-b and IL-10 ensures control of in-
flammatory responses and promotes effective immunity against
pathogens while restricting excessive immunopathology to self
or inhaled particles (Li and Flavell, 2008).
TGF-b is expressed constitutively by a wide variety of leuko-
cytes and stromal cells within the lung, including alveolar macro-
phages, smooth muscle cells, fibroblasts, and the epithelium
(de Boer et al., 1998; Sullivan et al., 2009). Indeed, the lung
epithelium plays an active role in directing the immune response
to both pathogens and allergens. Manipulation of epithelial
genes to promote TGF-b signaling results in an exacerbation of
house dust mite (HDM)-induced pathology (Gregory et al.,
2010) and loss of tolerance to inhaled ovalbumin (Gregory
et al., 2013). Epithelial cells can release chemokines and cyto-
kines including IL-6, TNF-a, IFN-a, IFN-b, GM-CSF, MIP-1a
(CCL3), and MCP-1 (CCL2) upon antigen stimulation, culmi-
nating in cell recruitment and activation (Lambrecht and Ham-
mad, 2012; Vareille et al., 2011). In an allergic context, epithelial
cell secretion of the cytokines IL-25, IL-33, and TSLP promote
Th2 cell and innate lymphoid type 2 cell (ILC2) recruitment (Li-
cona-Limo´n et al., 2013).
Expression of TGF-b is increased in the lung after both viral
and allergen challenge (Gibbs et al., 2009; Kariyawasam et al.,
2009; Schultz-Cherry and Hinshaw, 1996). Moreover, SNPs in
the promoter and coding regions of TGF-b (which result in
increased gene expression) have been linked to asthma suscep-
tibility (Li et al., 2007; Silverman et al., 2004). The crucial role
TGF-b plays in maintaining peripheral tolerance has long been
established, with global genetic deletion of TGF-b resulting in
early death from multi-organ inflammation (Shull et al., 1992).
Interestingly, targeted deletion of TGF-b signaling in CD4+
T cells results specifically in inflammation at mucosal sites,
including the airways (Li and Flavell, 2008). We and others
have previously determined that systemic neutralization ofmunity 43, 945–958, November 17, 2015 ª2015 The Authors 945
TGF-b via antibodies has variable effects on lung remodeling,
inflammation, and airway hyperactivity (AHR), depending on
the route of allergen exposure (Fattouh et al., 2008; McMillan
et al., 2005).
It has been postulated that asthma results from a loss of toler-
ance to harmless airborne particles; we hypothesized that a local
imbalance of TGF-b in the lung might modulate this loss of toler-
ance. In order to investigate the specific role of epithelial-derived
TGF-b in directing the pulmonary immune response to inhaled
allergen, we generated mice with a conditional deletion of
Tgfb1 in epithelial cells. Mice lacking epithelial-derived TGF-b1
displayed no baseline immune defects but were protected
from the effects of allergen exposure, exhibiting diminished
airway inflammation and improved lung function. Although pul-
monary IL-13+ Th2 cells were unaffected, the frequency of
IL-13+ ILC2s was significantly reduced. We found that ILCs ex-
pressed TGF-bRII and moreover, exposure of airway ILCs to
TGF-b increased cell chemoactivity. This novel interaction be-
tween ILCs and TGF-b derived from the lung epithelium is a
crucial pathway leading to the generation of early allergic im-
mune responses and reinforces the concept that resident tissue
stromal cells are key facilitators in the inception of local mucosal
immunity.
RESULTS
Epithelial-Derived TGF-b Is Critical for the Development
of Allergic Immunity
TGF-b is secreted by many cells within the lung and is critical for
a range of immune functions, including the generation and regu-
lation of effector T cell subsets, which have key roles at mucosal
surfaces. In order to determine how pulmonary epithelial-derived
TGF-b directs lung immunity, we generated mice lacking TGF-b
specifically in the bronchial epithelium (Ccsp-creTgfb1/) and
assessed the effect of allergen exposure. Deletion of TGF-b in
the airway epitheliumwas achieved by crossingmice expressing
a TGF-b1 gene containing loxP sites flanking exon 6 with club
(previously Clara) (Winkelmann and Noack, 2010) cell secretory
protein (CCSP-rtTA/tetO-Cre) transgenic mice (Figure S1A; Azhar
et al., 2009; Perl et al., 2009). This inducible system allows the
lungs to develop normally until administration of doxycycline
(DOX) in adulthood, thereby avoiding potentially adverse effects
of TGF-b deletion on lung organogenesis and development.
Cre recombinase expression in the lung was restricted to
epithelial cells of the conducting airways and was detectable
within 48 hr of intraperitoneal dosing with DOX with very little
non-specific expression in other lung structural or resident cells
(Figure S1B). 72 hr after treatment with DOX, TGF-b1 was
deleted in bronchiolar epithelial cells in transgenic mice whereas
expression was unaffected in littermate controls (Figure S1C).
Additionally, we sorted club epithelial cells based on surface
expression of CCSP. mRNA levels of TGF-b1 were unaffected
in the CCSPCD45+ cell fraction of Ccsp-creTgfb1/ mice
compared to control mice but were greatly decreased in the
club cell fraction (CCSP+CD45), demonstrating the specificity
of TGF-b1 deletion in epithelial cells of the conducting airways
(Figure S1D). Global and T-cell-specific TGF-b knockout mice
develop lymphoid proliferative disease and widespread inflam-
mation at baseline (Kulkarni et al., 1993; Li et al., 2006). In946 Immunity 43, 945–958, November 17, 2015 ª2015 The Authorscontrast,Ccsp-creTgfb1/mice exhibited no significant inflam-
mation in the blood, spleen, bone marrow, or mediastinal lymph
nodes (Figures S1E–S1H). Functional TGF-b is vital for suppres-
sion of inappropriate immune responses to innocuous airborne
particles/antigens, such as dust and dander (Fattouh et al.,
2008). Given the importance of the pulmonary epithelial barrier
in defense against these antigens, we hypothesized that epithe-
lial-derived TGF-b would be important in the regulation of im-
mune responses to inhaled allergens. Mice were pre-treated
with DOX or vehicle (mock) 72 hr prior to intra-nasal administra-
tion of the common aeroallergen house dust mite extract (HDM)
for 3 weeks in a continuous dosing protocol. Ablated epithelial
expression of TGF-b was maintained after 3 weeks of HDM
exposure in Ccsp-creTgfb1/ mice (Figure 1A). We observed
no compensatory increase in expression of Tgfb2 or Tgfb3 in
the lung tissue of mice lacking epithelial-derived TGF-b1 expres-
sion (Figure S2A). Because doxycycline is a potent antibiotic and
long-term exposure has previously been shown to alter lung
structure, we conducted parallel experiments in littermate con-
trol mice with homozygous Tgfb1fl/fl but lacking either CCSP-rtTA
or tetO-Cre. DOX administration alone did not significantly affect
the allergic phenotype; HDMexposure promoted similar levels of
airway hyperreactivity (AHR), inflammation, and eosinophilia in
both DOX- and mock-treated littermate control groups (Figures
S2B–S2F). These results indicate that mice deficient in epithe-
lial-derived TGF-b are immunologically normal under homeo-
static conditions.
In contrast, Ccsp-creTgfb1/ mice had significantly reduced
AHR in response to HDM exposure with ameliorated airway
resistance and compliance compared to mock-treated mice
(Figures 1B and S2G). Recruitment of cells to the airway lumen
was also reduced in Ccsp-creTgfb1/ mice (Figure 1C),
although recruitment to the lung tissue was unaffected (Fig-
ure 1D). This was reflected in the similar levels of peribronchial
inflammation as measured by histological scoring of lungs be-
tween Ccsp-creTgfb1/ mice and mock-treated mice (Figures
1E and S2H). Specific epithelial deletion of TGF-b greatly
diminished HDM-induced pulmonary eosinophilia, a hallmark
feature of asthma (Figures 1F and S2I). This was accompanied
by a decrease in the amount of the eosinophilic chemokine eo-
taxin-2 in the airways but not the lung (Figures 2A and 2B), as
well as the eosinophil growth and survival factor IL-5, which
was dramatically reduced in both the airways and lung tissue
(Figures 2C and 2D). The effect seemed to be highly selective
for eosinophils because the numbers of neutrophils and macro-
phages and the amounts of their associated chemoattractants
were unaffected (Figures 1F and S3A–S3C). The lack of epithe-
lial-derived TGF-b resulted in a small basal increase in pulmo-
nary eosinophil numbers in these mice (Figure 1F), which was
not attributable to DOX treatment because the same phenotype
was not observed in incomplete transgenic littermate controls
that lack the genetic machinery to excise epithelial-derived
TGF-b (Figure S2F). Thus, epithelial-derived TGF-b is a crucial
mediator of allergen-driven eosinophil recruitment to the lung.
IL-4 is classically involved in immunoglobulin class switching
for the generation of allergen-specific immunoglobulin E (IgE)
and is characteristic of atopic asthma. We determined that the
lack of epithelial-derived TGF-b completely abrogated the IL-4
response in the lung (Figure 2E) and led to diminished total and
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Figure 1. Mice Lacking Epithelial-Derived
TGF-b Have Reduced Airway Hyperreac-
tivity, Airway Inflammation, and Eosinophilia
(A) TGF-b1 expression in the epithelium of Ccsp-
creTgfb1/ (DOX)- and Tgfb1+/+ (mock)-treated
mice after intranasal house dust mite (HDM) or
PBS administration for 3 weeks. Original magnifi-
cation 203.
(B) Airway hyperreactivity measured by airway
resistance to ascending methacholine concentra-
tion (baseline; BL).
(C and D) Cell counts in the (C) airways and (D) lung
tissue.
(E) Hematoxylin and eosin-stained lung tissue after
HDM administration.
(F) Numbers of macrophages (MAC), eosinophils
(EOS), and neutrophils (NEU) in the airways.
Mann-Whitney *p < 0.05, **p < 0.01, and
***p < 0.001. Data shown are from one experiment
representative of two independent experiments
with a total of n = 10–12 mice per group. Box and
whisker plots depict the median and IQR and
minimum and maximum values. Line graphs
and bar charts are expressed as mean ± SEM. See
also Figures S1 and S2.allergen-specific IgE (Figures 2F and 2G). TGF-b is known to
induce IgA production and global TGF-b-deficient mice are un-
able to mount an effective IgA response (van Ginkel et al.,
1999). However, there was no effect on local pulmonary IgA
levels in mice specifically lacking epithelial-derived TGF-b (Fig-
ures 2H and S3D), indicating that TGF-b derived from the airway
epithelium is necessary for the generation of IL-4 in response to
allergen challenge and subsequent production of IgE.
IL-13, the prototypic type 2 cytokine, is a critical driver of AHR
and coincident with the diminished AHR, we found that IL-13
protein was reduced both in the lung tissue and airways of
HDM-exposed Ccsp-creTgfb1/ mice (Figures 2I and 2J).
There was also a concomitant reduction in pulmonary Il13
mRNA levels in these mice (Figure 2K), implying that epithelial-
derived TGF-b drives type 2 immune responses and the ensuing
AHR after HDM exposure.
Epithelial-Derived TGF-b Specifically Affects
Accumulation of ILC2s rather than IL-13+ Th2 Cells
TGF-b is a crucial controller of T cell lineage differentiation.
Because we observed a reduction in type 2 immunity and
because TGF-b has also been shown to suppress Th2 cell differ-Immunity 43, 945–958, Nentiation (Travis and Sheppard, 2014), we
enumerated these cells in lungs from
Ccsp-creTgfb1/ and control mice. As
expected, in mock-treated mice, HDM
exposure resulted in an increase in the
frequency of Th2 (CD3+CD4+IL-13+) cells
(gating strategy shown in Figure S3E).
However, despite the reduction in pulmo-
nary IL-13 concentrations in Ccsp-
creTgfb1/ mice, the numbers of IL-13+
Th2 cells were comparable in both the
lung and BAL from Ccsp-creTgfb1/and control mice (Figures 3A and 3B). We did, however, observe
a decrease in the number of IL-4+ T cells (Figure S3F). The
observed reduction in IL-4+ T cells and no change in IL-13+
T cells inCcsp-creTgfb1/mice is probably due to the complex
and differential interactions between GATA-3 and the IL-4 and
IL-5/13 promoter sites (Van Stry and Bix, 2011).
Similarly, the absence of epithelial-derived TGF-b had no
effect on development of either Th17 or Th1 cells (Figures 3C,
3D, S3G, and S3H) or the production of cytokines IL-17 or
IFN-g (Figures S3I and S3J), which might drive part of the resid-
ual inflammation observed in the lungs of Ccsp-creTgfb1/
mice despite reduced Th2 cytokines. The numbers of IL-10+
Treg and Foxp3+ Treg cells were also not different in lungs
fromCcsp-creTgfb1/mice (Figures 3E and 3F). Thus, although
lymphocyte-derived TGF-b has been reported to have profound
effects on Th cell differentiation in vitro and in other in vivo model
systems, it appears that local epithelial-derived TGF-bmakes lit-
tle contribution to directing Th cell subset generation at the pul-
monary mucosa.
ILCs are postulated to be an important source of IL-13 in
both allergic and viral responses—particularly contributing to
the development of AHR (Kim et al., 2012). Therefore, weovember 17, 2015 ª2015 The Authors 947
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Figure 2. Epithelial-Derived TGF-b Is Necessary for the Generation of Hallmark Features of Allergic Airways Disease
(A and B) Levels of eotaxin-2 in the (A) BAL and (B) lung of Ccsp-creTgfb1/ (DOX) and Tgfb1+/+ (mock) mice after intranasal house dust mite (HDM) or PBS
administration.
(C and D) IL-5 levels in the (C) BAL and (D) lung.
(E) Concentration of IL-4 in lung tissue.
(F and G) Serum levels of (F) IgE and (G) HDM-specific IgE.
(H) IgA in lung tissue.
(legend continued on next page)
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Figure 3. IL-13+ ILCs rather than T Effector Cell Subsets Are Preferentially Reduced in Ccsp-creTgfb1–/– Mice
(A and B) Frequencies of Th2 cells in the (A) lung tissue and (B) airways of Ccsp-creTgfb1/ (DOX)- and Tgfb1+/+ (mock)-treated mice after intranasal house dust
mite (HDM) or PBS administration.
(C–F) Numbers of (C) Th17 cells, (D) Th1 cells, (E) IL-10+ Treg cells, and (F) FOXP3+ Treg cells in the lung.
(G and H) Frequencies of IL-13+lineageCD45+ICOS+ ILCs in the (G) lung and (H) airways.
Mann-Whitney **p < 0.01. Data shown are from one experiment representative of two independent experiments with a total of n = 10–12 mice per group. Box and
whisker plots depict the median and IQR and minimum and maximum values. See also Figures S3–S5.enumerated the IL-13+ ILC2 population defined here as IL-13+
LinICOS+CD45+ cells (gating strategy outlined in Figures S4A
and S4B). Further analysis of these IL-13+ ILCs shows that these
cells strongly expressed CD127, Thy1, and ST2 (but not CD3,
TER-119, CD11b, GR1, CD45R, CD4, CD5, CD8, NK1.1,
CD11c, TCR-b, or TCR-gd) (Figures S4C and S4D). Although
epithelial-derived TGF-b had no effect on the numbers of
IL-13+ T cells, the numbers of IL-13+ ILC2s were significantly
reduced in Ccsp-creTgfb1/ mice compared to control mice
in both the lungs and airways (Figures 3G, 3H, and S5A) as
were both IL-4+ and IL-5+ ILCs (Figures S5B and S5C), corre-
lating with the decreased concentrations of these cytokines
measured in the lung. Total ILC2s (including non-activated i.e.,
not expressing cytokine but expressing the ILC2 transcription
factor GATA-3) were also reduced in lung and bronchoalveolar
lavage (BAL) of allergen-treatedCcsp-creTgfb1/mice (Figures
S5D and S5E), despite concentrations of the ILC-inducing cyto-
kine IL-33 being equivalent in control and Ccsp-creTgfb1/(I and J) Levels of IL-13 in the (I) lung tissue and (J) BAL fluid.
(K) Il13 mRNA levels in lung tissue.
Mann-Whitney *p < 0.05 and **p < 0.01. Data shown are from one experiment rep
group. Box and whisker plots depict the median and IQR and minimum and max
Immice (Figure S5F). This affect was restricted to the ILC2 popula-
tion, as shown by the fact that numbers of NK cells and ILC3s
(IL-17+) were comparable in Ccsp-creTgfb1/ and control
mice (Figures S5G and S5H).
These findings establish that epithelial-derived TGF-b has a
highly cell-selective effect and rather than contributing here to
the differentiation of effector T cell subsets, it appears to be
critical for the accumulation of type 2 ILCs in the lung and air-
ways after allergen exposure. Thus, epithelial-derived TGF-b is
necessary for the development of key hallmark features of
allergic airways disease including increased ILC2s, type 2 cyto-
kine induction, AHR, eosinophilia, and IgE.
Epithelial-Derived TGF-b Acts in Concert with IL-33 to
Facilitate Mucosal Inflammation
ILC2s are induced by a trio of epithelial cytokines of variable
potency: IL-33, IL-25, and TSLP (Barlow et al., 2013). Because
the IL-13+ ILC2 population appears to be strongly influencedresentative of two independent experiments with a total of n = 10–12 mice per
imum values. See also Figure S3.
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Figure 4. Epithelial-Derived TGF-b Enhances IL-33-Mediated Inflammation
(A) Levels of TGF-b in the BAL of control (Tgfb1+/+) andCcsp-creTgfb1/mice treatedwith a single dose of either rIL-33 or HDMasmeasured by TGF-b bioassay.
(B) TGF-b in the BAL of Ccsp-creTgfb1/ (DOX) and Tgfb1+/+ (mock) mice after 1 week of rIL-33 (or PBS) administration.
(C) TGF-b1 expression in the epithelium in DOX- and mock-treated mice. Original magnification 203.
(D and E) Cell counts in the (D) airways and (E) lung tissue.
(F) Numbers of macrophages (MAC), eosinophils (EOS), and neutrophils (NEU) in the airways.
(G–I) Levels of (G) Eotaxin-2 and (H) IL-5 in the BAL and (I) Il5 mRNA levels in the lung tissue.
Mann-Whitney *p < 0.05 and **p < 0.01. Data shown are from one experiment representative of two independent experiments with a total of n = 10–12 mice per
group. Box and whisker plots depict the median and IQR and minimum and maximum values. Bar charts are expressed as mean ± SEM. See also Figures S5
and S6.by epithelial-derived TGF-b, we further investigated the relation-
ship between ILC-inducing cytokines and TGF-b by utilizing a
week-long model of recombinant IL-33 (rIL-33) administration
to induce substantial ILC2 numbers in the absence of an anti-
gen-specific Th2 cell response (as observed in response to950 Immunity 43, 945–958, November 17, 2015 ª2015 The Authorsallergen exposure over a 3 week period). To determine whether
IL-33 directly influenced TGF-b release, we first administered a
single dose of murine rIL-33 (1 mg) intranasally to control
(Tgfb1+/+) mice and BAL fluid was recovered 1, 4, and 18 hr later
(Figure 4A). rIL-33 administration induced a rapid release of
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Figure 5. Epithelial-Derived TGF-b Enhances IL-13+ ILC Responses during IL-33-Driven Inflammation
(A and B) Frequencies of IL-13+lineageCD45+ICOS+ ILCs in the (A) airways and (B) lung tissue in Ccsp-creTgfb1/ (DOX) and Tgfb1+/+ (mock) mice after rIL-33
(or PBS) administration.
(C and D) Th2 cells in the (C) lung tissue and (D) airways.
(E and F) Levels of IL-13 in the (E) BAL fluid and (F) lung tissue.
(G) Il13 mRNA levels in lung tissue.
Mann-Whitney *p < 0.05, **p < 0.01. Data shown are from one experiment representative of two independent experiments with a total of n = 10–12mice per group.
Box and whisker plots depict the median and IQR and minimum and maximum values.active TGF-b into the airway lumen. Similarly, a single dose of
HDM resulted in comparable TGF-b release (Figure 4A). Interest-
ingly, this enhanced production of bioactive TGF-b after HDM
stimulation was not observed in mice specifically lacking epithe-
lial-derived TGF-b (Figure 4A, white box). This indicated that
IL-33 specifically enhanced release of TGF-b from the lung
epithelium, which expresses the IL-33 receptor ST2 (Figure S5I),
since there is no compensatory release of TGF-b in Ccsp-
creTgfb1/ mice that still contained TGF-b-sufficient leuko-
cytes and other pulmonary cells. However, ST2-deficient mice
exposed to 3 weeks of HDM display equivalent levels of TGF-b
release (data not shown), indicating that functional IL-33
signaling was not absolutely required for release of TGF-b. The
secretion of epithelial-derived TGF-b was maintained after
multiple doses of both rIL-33 (Figure 4B) and HDM (Figure S5J).
Immuno-histochemical staining of lung sections also localized
TGF-b to the bronchial epithelium after rIL-33 administration
(Figure 4C). As expected, in Ccsp-creTgfb1/ mice expression
of TGF-b in the epithelium was absent after rIL-33 treatment.
Pulmonary delivery of IL-33 in vivo is associated with type 2
inflammation mediated predominantly by ILC2s (Barlow et al.,
2013; Walker and McKenzie, 2012). A lack of epithelial-derivedImTGF-b resulted in a significantly reduced cellular infiltration to
the airway lumen rather than the lung tissue (Figures 4D, 4E,
and S6A). Differential cell counts revealed that the reduction in
IL-33-induced BAL inflammation was due to decreased recruit-
ment of both eosinophils and neutrophils in Ccsp-creTgfb1/
mice (Figure 4F). The reduction in BAL eosinophilia in the
Ccsp-creTgfb1/mice was probably due to reduced eosinophil
trafficking to the airways because lower levels of the key eosin-
ophil chemoattractant eotaxin-2 and also IL-5 were detected in
the BAL (Figures 4G and 4H). Similar findings were observed in
the lung (Figure S6B and S6C). Lung Il5 mRNA levels were also
reduced in Ccsp-creTgfb1/ mice (Figure 4I).
Mice that specifically lack TGF-b in their pulmonary epithelial
cells had significantly reduced ILC2 numbers in the airway lumen
after rIL-33 treatment (Figure 5A). In contrast, numbers of ILC2s
and Th2 cells within the lung tissue were unaffected (Figures 5B
and 5C). Th2 cells in the airway lumen also remained unchanged
(Figure 5D). After rIL-33 administration, the IL-13 response was
significantly decreased in the lungs and airways of Ccsp-
creTgfb1/ mice, at both protein and RNA levels (Figures 5E–
5G). Administration of exogenous TGF-b to Ccsp-creTgfb1/
mice restored the IL-33-induced increase in BAL inflammationmunity 43, 945–958, November 17, 2015 ª2015 The Authors 951
A B C
D E F G
H I
L M
J K
Figure 6. TGF-b Acts to Enhance ILC2 Activation
(A) TGF-bRII expression on ILCs defined as lineageCD45+ICOS+ in different organs (lymph nodes [LN]), with resident ILC populations in naive control
(Tgfb1+/+ ) mice.
(legend continued on next page)
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(Figure S6D). Airway eosinophilia and Th2 cell recruitment, which
was reduced in Ccsp-creTgfb1/ mice, was elevated to com-
parable levels as control IL-33-treated mice (Figures S6E and
S6F). There was also a partial restoration of ILC2 numbers and
IL-13 secretion in the Ccsp-creTgfb1/ mice treated with
rTGF-b (Figures S6G and S6H). The number of pulmonary ILCs
and the levels of Th2 cytokines were 10-fold greater in the
rIL-33 model of type 2 inflammation compared to that observed
in the allergen-induced allergic airways disease model. How-
ever, whereas the magnitude of the immune response was sub-
stantially increased, the effect of epithelial-derived TGF-b was
consistent in reducing IL-13+ ILC2 accumulation. Thus, TGF-b
secreted from airway epithelial cells is fundamental for the incep-
tion of type 2 immunity after multiple stimuli.
Pulmonary IL-13+ ILC2s Are Primed to Respond to
Epithelial-Derived TGF-b
Targeted deletion of TGF-b in the bronchial epithelium had a spe-
cific effect on IL-13+ ILC2 responses in the airways after expo-
sure to either allergen or rIL-33. We measured expression of
TGF-bRII on ILCs in different anatomical compartments of naive
control mice to determine whether cells in the airways are specif-
ically primed to respond to TGF-b. Indeed, we found a signifi-
cantly higher percentage of ILCs in the airway lumen-expressed
TGF-bRII compared to ILCs in the lung tissue, bonemarrow, lung
lymph nodes, or blood (Figures 6A and 6B), indicating that ILCs
in the airway lumen are primed to respond to TGF-b secreted in
response to inhaled environmental stimuli. Indeed, both HDM
and rIL-33 resulted in enhanced accumulation of TGF-bRII-ex-
pressing ILCs in the airways (Figure 6C).
During manipulation of an inflammatory response, reduced
accumulation of a particular cell type can occur as a result
of decreased recruitment or proliferation. We used Ki67
expression as a surrogate marker for proliferating cells and
found a very high percentage of ILCs expressing Ki67, both
non-activated (LinICOS+CD45+) and activated (cytokine
secreting), but no significant difference in the frequency of
proliferating total ILCs or ILC2s specifically in Ccsp-
creTgfb1/ mice (Figures 6D and 6E), indicating that TGF-b
derived from the epithelium is essential for accumulation of
ILCs in the airways.
Ccsp-creTgfb1–/– Mice Have Enhanced GATA-3
Regulation
GATA-3 is the master transcription factor for induction of Th2
cytokines in both T cells and ILCs (Hoyler et al., 2012). We
assessed whether GATA-3 levels were reduced in Ccsp-
creTgfb1/ mice to account for their lower levels of Th2 cyto-
kines such as IL-13 and IL-5. We found no change in GATA-3(B) FACs plot showing TGF-bRII expression on ILCs.
(C) TGF-bRII expression on ILCs from HDM and rIL-33-treated control mice.
(D and E) Proliferation defined as Ki67 expression on (D) ILC and (E) ILC2 (IL-13+)
after rIL-33 (or PBS) administration.
(F and G) GATA-3 expression on (F) ILC and (G) ILC2 (IL-13+) populations in the
(H) mRNA levels of Gata3 in the lung.
(I–L) mRNA levels of GATA-3 regulatory proteins (I) Zfpm1, (J) Lef1, (K) Zbtb32, a
(M) Sox4 mRNA levels in FACs-sorted CD4+ T cells and ILCs.
Mann-Whitney *p < 0.05; n = 7–12 mice per group. Box and whisker plots dep
expressed as mean ± SEM.
Imexpression in the lung either at the protein or mRNA level after
TGF-b depletion in the pulmonary epithelium (Figures 6F–6H).
However, control of GATA-3 activity is mediated via binding
of regulatory elements to the transcription factor (rather than
altered expression of GATA-3 protein), which enhance or
retard binding to type 2 promoters and hence production of
type 2 cytokines (Hossain et al., 2008; Kuwahara et al., 2012;
Miaw et al., 2000; Zhou et al., 2001). We investigated the
expression of known GATA-3 regulatory proteins and found
no change in the mRNA levels of zinc finger protein multitype 1
(Zfpm1) (Figure 6I), Lymphoid Enhancer Factor 1 (Lef1) (Fig-
ure 6J), or zinc finger and BTB domain containing 32
(Zbtb32) (Figure 6K). In contrast, a significant increase in
mRNA levels of the GATA-3-suppressive transcription factor
Sox4 (sex determining region Y, box 4) was observed in lung
tissue of Ccsp-creTgfb1/ mice (Figure 6L). In sorted cells,
the increase in Sox4 was found to be specific to ILCs and
levels were unchanged in T cells from Ccsp-creTgfb1/
mice (Figure 6M). Therefore, local TGF-b production can
induce altered GATA-3 function via the increased expression
of the GATA-3 regulatory protein Sox4.
TGF-b Acts to Enhance Airway ILC Chemoactivity
Next, we questioned whether the reduced number of ILCs in the
airways was due to a deficiency in accumulation. TGF-b has pre-
viously been shown to increase cell migration of both immune
and stromal cells via two mechanisms. It can act directly as a
chemoattractant and indirectly by upregulating chemokine re-
ceptors and hence sensitivity to chemokines (Castriconi et al.,
2013; Happel et al., 2008). With the TAXIScan chemotaxis assay
system, we assessed the capacity of ILCs sorted from the airway
lumen of rIL-33-treated mice to migrate along gradients of rIL-33
or rTGF-b (Figure 7A). We found that exposure of ILCs to a
gradient of rTGF-b resulted in a significant increase in both the
distance traveled by the ILCs (Figure 7B) and also their velocity
(Figure 7C), when compared to cells exposed to PBS or rIL-33.
However, this increased migration was non-directional, with no
significant differences in the directionality component between
either group (Figure 7D). We also examined the movement of
ILCs from Ccsp-creTgfb1/ mice, finding no significant differ-
ence in their migratory capacity compared to control mice (Fig-
ures S6I and S6J). Therefore, there were no intrinsic defects in
the capacity of ILCs from Ccsp-creTgfb1/ mice to respond
to and be activated by pulmonary epithelial-derived TGF-b.
These data suggest that TGF-b does not act as a chemotactic
factor for ILCs but rather increases the basal migration of ILCs,
leading to greater overall cell movement. This might ‘‘prime’’
the cells for enhanced responsiveness to additional chemotactic
stimuli. Taken together, our data demonstrate that the localpopulations in the lung of Ccsp-creTgfb1/ (DOX) and Tgfb1+/+ (MOCK) mice
lung.
nd (L) Sox4 in lung tissue.
ict the median and IQR and minimum and maximum values. Bar charts are
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Figure 7. TGF-b Induced Chemoactivity
(A) Plots showing cell tracking of individual migrating cells exposed to chemoattractant gradients over 60 min. Cells were realigned to show the same point of
origin.
(B–D) Accumulated distance (B), track velocity (C), and directionality (D) of individual cells. ILCs (lineageCD45+ICOS+) were recovered from the airway lumen of
control (Tgfb1+/+) mice treated with rIL-33 for 1 week. Cells were then exposed to gradients of rIL-33 (20 mg/ml), rTGF-b1 (5 mg/ml), or PBS and cell movement
assessed by TAXIScan methodology.
Data were pooled from three individual experiments with a minimum total of nR 50 cells tracked per group. Dot plots depict median values. See also Figure S6.mucosal environment and specifically epithelial-derived TGF-b
is a crucial driver of the early allergic immune response to inhaled
stimuli in the lung.
DISCUSSION
Pulmonary epithelial cells play a pivotal role in both the mainte-
nance of immune homeostasis and defense against pathogens
in the lung. In order to investigate the cellular networks required
for the molecular pathways that maintain this balance between
tolerance to inhaled particles and development of inflammation,
we generated inducible bronchial epithelial cell-specific knock-
outs of TGF-b1. In contrast to global and T cell-specific TGF-b
knockouts, mice lacking epithelial-derived TGF-b displayed no
baseline immune defects but were protected from pathophysio-
logical consequences upon exposure to inhaled allergen. In
response to HDM exposure, Ccsp-creTgfb1/ mice displayed
a reduction in key features of asthma pathology, namely dimin-
ished AHR, eosinophilia, pulmonary inflammation, type 2 cyto-
kines, and IL-4-driven IgE production. We have determined
that this lack of IL-13-driven allergic pathophysiology was spe-
cifically due to a reduction in pulmonary IL-13+ ILC2 activation
and accumulation.954 Immunity 43, 945–958, November 17, 2015 ª2015 The AuthorsMoreover, our data show that ILCs in the airway lumen are
primed to respond to TGF-b, as a result of high cell surface
expression of TGF-bRII, and we demonstrated that TGF-b
enhanced the migratory activity of ILCs. Delivery of rIL-33 to
the lung, which is known to result in the generation of ILC2s,
induced a rapid release of TGF-b into the airways. Because
Ccsp-creTgfb1/ mice had limited numbers of pulmonary
ILCs, one can infer that epithelial-derived TGF-b is essential for
the accumulation of these cells in the lung, acting downstream
of the alarmin IL-33 to initiate a type 2 skewed immune response.
In summary, this interaction between ILCs and TGF-b derived
from the lung epithelium is a key pathway in the generation of
allergic phenotype.
A variety of resident pulmonary cells are able to secret TGF-b,
including lung stromal cells as well as infiltrating leukocytes.
Here we showed that specific depletion of TGF-b in the bronchial
epithelium (rather than alveolar epithelial cells or alveolar macro-
phages) resulted in a very selective immune defect with profound
consequences for disease pathology. Epithelial cells in the lung
act as sensors, sampling the inhaled environment. The activation
of pathogen-associated molecular pattern molecules (PAMPs)
and damage-associated molecular pattern molecules (DAMPs),
including the alarmin IL-33 in epithelial cells, both initiates and
perpetuates the inflammatory response to pathogens and aller-
gens. Thus, local environmental cues influence both cytokine
production and receptor expression on structural cells and leu-
kocytes. Our findings place TGF-b as a potent modulator of local
immune responses with substantial consequences for systemic
immunity.
We demonstrated that a greater proportion of ILCs expressed
TGF-bRII in the airway lumen compared to any other compart-
ment examined. These data indicated that IL-13+ ILC2s might
be intimately associated with the pulmonary epithelium and
that their function is influenced by the local cytokine milieu.
Indeed, a previous study has shown that the local cytokine envi-
ronment is critical for the generation of distinct cytokine signa-
tures. A unique human ILC-1 subset was identified that showed
the hallmark of TGF-b imprinting and activation (Fuchs et al.,
2013). Interestingly, this subset was shown to reside specifically
in the intraepithelial nichewithin the gut. Although the authors did
not comment on the in vivo cellular source for TGF-b in the gut, it
is known that intestinal epithelial cells, as in the lung, can express
TGF-b (Avery et al., 1993). Accumulation of cells within tissue is
the net result of recruitment and/or proliferation. We determined
that TGF-b enhances the migratory capacity of ILCs, which are
highly proliferative, collectively resulting in increased local
numbers of these cells. The pulmonary epithelium expresses a
range of molecules that enable rapid sensing and reaction to
inhaled particles (Lambrecht and Hammad, 2012). The data pre-
sented here add TGF-b to this list and support the hypothesis
that interaction between local tissue-resident cells and leuko-
cytes dictates the development of either protective or inflamma-
tory immune responses.
GATA-3 is a requirement for generation of the ILC2 phenotype,
with ectopic expression of GATA-3 inducing de novo expression
of type 2 cytokines (Hoyler et al., 2012; Zhou, 2012). We hypoth-
esized that the reduction in type 2 cytokines in Ccsp-
creTgfb1/ mice was due to a change in GATA-3 expression;
however, we found no change in the proportion of GATA-3-pos-
itive ILCs. However, we determined that specific deletion of
TGF-b from the cells lining the airways was associated with
increased levels of the negative GATA-3 regulator Sox4 during
allergen exposure. It has previously been shown that Sox4 trans-
genic mice exhibit decreased ovalbumin-induced allergic airway
disease with lower AHR, IL-5, and eosinophilia (Kuwahara et al.,
2012). In contrast, Sox4 knockout mice show the opposite
phenotype and develop enhanced allergic immune responses.
Our data revealed that epithelial-specific deletion of TGF-b re-
sulted in increased expression of Sox4 in ILCs that inhibited
GATA-3-induced type 2 cytokine expression. Therefore, location
of cytokine-secreting cells is very important in determining the
nature, magnitude, and bias of the subsequent immune
response.
ILCs are considered to be generated from an Id2+ precursor
population resident in the bonemarrow that proliferate and traffic
though the blood tomucosal sites. Very little is understood about
the process bywhich ILCs are attracted to sites of immune insult.
Other innate and adaptive lymphoid populations express a
distinct pattern of chemokine and cytokine receptors and are at-
tracted to tissues via chemokine gradients. Recently, both PGD2
and to a much lesser extent IL-33 have been shown to be
chemotactic for human skin- and blood-derived ILC2s (XueImet al., 2014). However, as yet, we lack a complete understanding
of the repertoire of chemotactic factors and agents utilized by
ILCs. We have shown that TGF-b acts as a chemoactive factor
for ILCs. Previously, TGF-b has been shown to be required
both for the migration and maintenance of memory T cell popu-
lations at the gut mucosa (Zhang and Bevan, 2013). In combina-
tion, these findings underscore the critical role of TGF-b in
controlling the recruitment and retention of specific cell popula-
tions at mucosal surfaces.
Our data highlight the crucial role that TGF-b plays in regu-
lating immune responses, particularly at mucosal surfaces
where the threshold for generating immune responses must be
exquisitely regulated. Evidence for an association between the
innate cytokine IL-33 and TGF-b can be found in the gut where
IL-33 has recently been shown to enhance TGF-b1-mediated dif-
ferentiation of Treg cells in the bowel (Schiering et al., 2014). In
the lung, we have unraveled a pathway for initiation of Th2 cell
responses whereby IL-33 directly induces TGF-b release from
the pulmonary epithelium. IL-33-induced TGF-b enhances
migration of ILCs, which express the TGF-bRII. Thus, TGF-b is
critical for the development of a robust ILC2 response to allergen
challenge and initiation of allergic immunity. Our data provide
direct evidence for the instruction of immune cells by resident
stromal cells and reinforce the idea that the local environmental
milieu is pivotal in defining the nature and magnitude of immune
reactions.
EXPERIMENTAL PROCEDURES
Animals and Reagents
Mice expressing Cre recombinase under the control of the rat CCSP promoter
CCSP-rtTA/tetO-Cre (Perl et al., 2009) were crossed withmice carrying floxed al-
leles for Tgfb1 (Azhar et al., 2009) (JaTgfb1tm2.1Doe/J, Jackson Laboratory).
Intraperitoneal administration of 2 mg doxycycline (DOX) (Sigma-Aldrich)
induced epithelial expression of Cre and excision of TGF-b1 (Ccsp-
creTgfb1/). Control mice included mock (100 ml PBS i.p.)-treated mice that
received no DOX (Tgfb1+/+) and littermate controls treated with DOX or
mock, which carried homozygous floxed Tgfb1 but lacked either theCCSP-rtTA
(or tetO-Cre) allele and were therefore unable to excise Tgfb1. All mice were
used between 7 and 12 weeks of age, housed in specific-pathogen-free con-
ditions, and given food and water ad libitum. All procedures were conducted in
accordance with the Animals (Scientific Procedures) Act 1986.
Mice were administered either 25 mg (1 mg/ml protein weight solution dis-
solved in PBS) of house dust mite (HDM) extract (Greer) or 25 ml of PBS intra-
nasally 5 times a week for 3 weeks. Mice were culled 4 hr after the final HDM or
PBS dose. Carrier-free recombinant murine IL-33 (1 mg per dose in 25 ml PBS)
(eBioscience) was administered 3 times a week for 1 week and mice culled
18 hr after the final dose. In other experiments, mice were administered
50 ng rTGF-b1 in PBS (R&D Systems) intranasally with or without rIL-33.
Lung Function
Airway hyperresponsiveness in response to increasing doses of methacholine
(10–300 mg/ml; Sigma-Aldrich) was measured as previously described using
the Flexivent system (Scireq) (Saglani et al., 2009).
Cell Recovery
Bronchoalveolar lavage (BAL) was performed by washing the airways three
times with 400 ml of PBS, after centrifugation supernatants were stored at
80C for further analysis and cells resuspended in 500 ml of complete media
(RPMI, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin)
(GIBCO, Life Technologies). The left and inferior lung lobes were chopped
and digested in complete media supplemented with 0.15 mg/ml collagenase
(Type D; Roche Diagnostics) and 25 mg/ml DNase (Type 1; Roche Diagnostics)
for 1 hr at 37C. Tissue was then passed through a 70 mm sieve (BDmunity 43, 945–958, November 17, 2015 ª2015 The Authors 955
Bioscience), washed, and resuspended in 1 ml of complete media. Bone
marrow (recovered from the left femur) and mediastinal lung draining lymph
nodes were passed through a 70 mm sieve, washed, and resuspended in
1 ml of complete media. Red blood cells in 200 ml whole blood were lysed
and the remaining leukocytes were washed twice and then resuspended in
1 ml of complete media.
Flow Cytometry
For intracellular staining of cytokines, cells were stimulated with PMA (Sigma-
Aldrich)/ionomycin (Emdchemicals) in the presence of Brefeldin A (Sigma-Al-
drich) for 3.5 hr at 37C. Cells were washed and incubated for 20 min with
rabbit serum (Sigma-Aldrich) prior to staining for extracellular antigens in 5%
FCS/1% BSA in PBS for 30 min at 4C. All antibodies were purchased from
eBioscience with the exception of ICOS (Biolegend), TGF-bRII (R&D Systems),
and T1/ST2 (MD Bioproducts). Cells were washed, fixed, and permeabilized
using Fix/Perm kit (eBioscience) before being stained for intracellular antigens.
Analysis was performed with Fortessa II and cell sorting on Aria III (BD
Biosciences).
Club/Clara Cell Sorting
Club/Clara cells were sorted as described (Wang et al., 2012) prior to deter-
mining the level of Tgfb1mRNA in the club (CCSP+CD45) and CCSPCD45+
cell fractions.
Measurement of Cytokines and Immunoglobulins
Themiddle lung lobewas homogenized at 50mg/ml in HBSS (GIBCO) contain-
ing protease inhibitor tablets (Roche Diagnostics) and centrifuged at 800 3 g
for 20 min. Lung homogenate supernatants were used to analyze cytokines
and immunoglobulins and serum to analyze immunoglobulins. Paired anti-
bodies for murine IgE, IgA, IL-4, IL-5 (BD Biosciences), IL-13 (eBioscience),
IL-33, KC, MIP-2, Eotaxin-2, and MCP-1 (R&D Systems) were used in stan-
dardized sandwich ELISAs according to the manufacturer’s protocol. HDM-
specific IgE was measured in the serum as previously described (Saglani
et al., 2009). TGF-b in BAL fluid was measured by bioassay as previously
described (Tesseur et al., 2006).
Lung Inflammation Scoring
Haematoxylin and eosin-stained lung sections were scored blindly for lung in-
filtrates where scores correspond to 1 (small pocket of infiltrate), 2 (small
pocket of infiltrate less than three cells deep inmore than one airway or vessel),
3 (more than one but less than 50%of airways and vessels have large infiltrates
more than three cells deep), 4 (most airways and vessels have large infiltrates),
and 5 (majority of airways and vessels have large infiltrates and cells present in
alveolar bed).
Real-Time PCR
Total RNA was extracted from 50 to 100 mg of lung tissue (postcaval lobe)
using a QIAGEN RNeasy Mini Kit (QIAGEN). Total RNA (1 mg) was reverse tran-
scribed into cDNA using a High Capacity cDNA Reverse Transcription Kit (Life
Technologies) according to themanufacturer’s instructions. Real-time PCR re-
actions were performed using fast-qPCR mastermix (Life Technologies) on a
Viaa-7 instrument (Life Technologies) with TaqMan primer sets for murine
Il13, Il5, Gata-3, Zfpm1, Lef1, Zbtb32, Sox4, Tgfb1, Tgfb2, and Tgfb3 plus
housekeeping genes Gapdh and Hprt (Life Technologies). Gene expression
was analyzed using the change-in-threshold DDCt- method using Hprt as
control.
Immunofluorescence and Immunohistochemistry
Paraffin sections were stainedwith rabbit anti-cre antibody (MerckMillipore) or
rabbit anti-TGF-b antibody (BD Biosciences) using an avidin/biotin staining
method.
TAXIScan Chemotaxis Assay
Control (Tgfb1+/+) and Ccsp-creTgfb1/ mice were administered rIL-33 and
cells recovered from the airway lumen. ILC population (lineageCD45+ICOS+)
was sorted using an Aria III (BD Biosciences). For real-time analysis of
migrating ILCs, a 12-channel TAXIScan was used in conjunction with a 4 mm
chip as previously described (Kanegasaki et al., 2003), according to the man-956 Immunity 43, 945–958, November 17, 2015 ª2015 The Authorsufacturer’s protocol (Effector Cell Institute). After alignment of cells, a 1 ml vol-
ume of rIL-33 (20 mg/ml), rTGF-b (5 mg/ml), or PBS (negative control) was then
added to the side of the chamber opposite the cells to generate a gradient.
Sequential images of migrating cells were generated from individual jpegs
processed with ImageJ (NIH, RRID: nif-0000-30467), equipped with the
manual tracking and chemotaxis tool plugins (Ibidi). Directionality was calcu-
lated by dividing the Euclidean distance by the observed accumulated dis-
tance for each tracked cell, with a value of 1 indicative of linear migration.
Accumulated distances refer to the total distances traveled by a particular cell.
Statistical Analysis
All data were analyzed with Graph Pad Prism 5 (GraphPad, RRID: rid_000081).
Box and whisker plots depict the median and IQR and line graphs and bar
charts are expressed as mean ± SEM and data analyzed with non-parametric
Mann-Whitney U test where significance was defined as *p < 0.05, **p < 0.01,
and ***p < 0.001.
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